However, a 2021 final analysis revealed no OS benefit in the ITT population.[58,59] IMpassion131(NCT03125902) was a phase III, randomized, placebo-controlled, double-blind trial of first-line paclitaxel with or without atezolizumab for patients with unresectable locally advanced or metastatic TNBC.
The study included 651 patients, 45% of whom had PD-L1â€“positive TNBC.
This trial also did not demonstrate a benefit from the addition of atezolizumab to paclitaxel in this population.[60] Accordingly, the sponsor voluntarily withdrew this approval.
IMpassion130 reported PFS data with a median follow-up of 12.9 months.[58]In the ITT population, PFS was improved with the addition of atezolizumab (median PFS, 7.2 months vs.